FundPlus

The Fund Portfolio Company Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development. Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a EUR 60M Series B financing. The round was led by Ackermans & van Haaren (AvH) and included participation from additional new investors, Driehaus Capital Management and Quest for Growth (QfG), as well as existing investors, BioGeneration Ventures (BGV), Capricorn Health-tech Fund (CHF), Fund , MINTS (University of Michigan), Perceptive Advisors, Qbic, PMV, V-Bio Ventures, VIB and Wellington Partners. You can read the full press release on our website www.fundplus.be.

The Fund portfolio company Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial (NAPISTAR 1-01, NCT06303505). The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC) TUB-040 in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC), who have exhausted other available treatment options. TUB-040 targets NaPi2b, a highly overexpressed antigen in ovarian cancer and lung adenocarcinoma. The candidate is the first to enter the clinic from the company’s growing pipeline and represents one of Tubulis’ two lead candidates developed using its proprietary suite of platform technologies, which enable the creation of uniquely matched ADCs with superior biophysical properties.  You can read the full article on our website www.fundplus.be.

We are extremely excited to announce that our portfolio company Cardior Pharmaceuticals is to be acquired by Novo Nordisk for up to 1.025 billion euros! Cardior Pharmaceuticals is a leader in RNA-targeting therapies that have the potential to prevent, repair and reverse diseases of the heart, and is to be acquired by Novo Nordisk for up to 1.025 billion euros, including upfront and additional milestone payments. At Fund , we first invested in Cardior’s Series B round in 2021, to bring the company’s main asset CDR132L into phase 2 clinical trials. Cardior perfectly exemplifies our strategy of investing in therapeutics which address unmet medical needs. In response to the news, our Principal @Halina Novak said: “Social impact is important for Fund , so we are thrilled to have contributed to the success of a promising European company en route to making a real difference in patient lives. It has been a privilege to work alongside the talented Cardior management team and the other investors – we will be watching future developments with great excitement.” Find out more in the full press release: https://lnkd.in/eya56ryv #acquisition #venturecapital #cardiovascular #heartdisease #rna #rnatherapeutics

We are extremely excited to announce that our portfolio company Cardior Pharmaceuticals is to be acquired by Novo Nordisk for up to 1.025 billion euros! Cardior Pharmaceuticals is a leader in RNA-targeting therapies that have the potential to prevent, repair and reverse diseases of the heart, and is to be acquired by Novo Nordisk for up to 1.025 billion euros, including upfront and additional milestone payments. At Fund , we first invested in Cardior’s Series B round in 2021, to bring the company’s main asset CDR132L into phase 2 clinical trials. Cardior perfectly exemplifies our strategy of investing in therapeutics which address unmet medical needs. In response to the news, our Principal @Halina Novak said: “Social impact is important for Fund , so we are thrilled to have contributed to the success of a promising European company en route to making a real difference in patient lives. It has been a privilege to work alongside the talented Cardior management team and the other investors – we will be watching future developments with great excitement.” Find out more in the full press release: https://lnkd.in/eya56ryv #acquisition #venturecapital #cardiovascular #heartdisease #rna #rnatherapeutics

We’re very proud to announce that our portfolio company Tubulis GmbH has successfully closed an upsized €128 million Series B round! The funds will be used to progress the company’s pipeline of next-gen ADCs for the treatment of solid tumors.   Tubulis has developed an impressive set of platform technologies which means they can push the boundaries on ADC design and have the flexibility to tackle a range of different types of tumors. We are excited to support their journey as the company continues its growth trajectory and path towards making a tangible difference to cancer patients.   Congratulations to CEO Dominik Schumacher and his team on this great step forward for Tubulis!   To find out more, you can read the full press release here: https://lnkd.in/eKp83xH9   #cancer #cancertreatment #solidtumors #funding #venturecapital